NEW YORK, May 11, 2026
Myrtelle announced new clinical and regulatory updates for its investigational gene therapy candidate MYR-101 during the upcoming American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting in Boston, Massachusetts. The company plans to showcase emerging clinical findings from its ongoing study evaluating MYR-101 for Canavan disease, a rare and fatal pediatric neurodegenerative disorder with no approved curative therapies currently available.
The presentations will also highlight Myrtelle’s regulatory progress under the FDA’s START Pilot Program, as well as manufacturing collaboration efforts supporting the company’s long-term commercialization strategy. MYR-101 is a first-in-class investigational gene therapy specifically designed to target oligodendrocytes and restore normal ASPA gene function, addressing the underlying biological cause of Canavan disease rather than only managing symptoms. Company executives stated that the ASGCT presentations represent an important milestone as Myrtelle advances toward a potential future Biologics License Application (BLA) submission and broader clinical development activities.
Clinical Data Highlight Therapeutic Progress in Canavan Disease
During the ASGCT scientific session titled “Beyond neurons: Glial-targeted gene and cell therapies for neurologic and ophthalmic diseases,” internationally recognized Canavan disease researcher Dr. Paola Leone will present updated findings from the ongoing MYR-101 clinical trial. According to the company, the presentation will include clinical observations from children treated with the investigational therapy, demonstrating encouraging signals of therapeutic activity and meaningful clinical improvement. Myrtelle stated that the therapy aims to restore expression of the aspartoacylase enzyme, which is critically deficient in patients with Canavan disease due to mutations in the ASPA gene.
The absence of this enzyme disrupts brain development, myelin production, and neurological function, eventually leading to severe motor impairment, seizures, feeding complications, and early mortality. Company representatives emphasized that current treatment options remain limited to supportive and palliative care, creating significant unmet medical need within the rare pediatric disease community. The company believes MYR-101 has the potential to alter disease progression by directly targeting the underlying genetic defect responsible for neurological degeneration. The ASGCT presentation is expected to further strengthen clinical understanding of glial-targeted gene therapy approaches in rare neurodegenerative disorders.
Advertisement
FDA START Pilot Program Supports Regulatory Advancement
Myrtelle also highlighted ongoing collaboration with the U.S. FDA through participation in the agency’s START Pilot Program, an initiative designed to accelerate development of promising therapies for serious rare diseases. The company stated that its inclusion in the FDA pilot framework supports closer regulatory interaction as MYR-101 advances through clinical development and manufacturing scale-up activities. In addition to the clinical data presentation, Myrtelle Chief Executive Officer Adrian Stecyk will participate in a sponsored symposium hosted by manufacturing partner Viralgen during ASGCT 2026. The session will focus on the pathway from gene therapy development through commercial manufacturing readiness and regulatory preparation.
According to the company, discussions will include manufacturing scalability, regulatory strategy, and key progress updates supporting future commercialization of MYR-101. Myrtelle noted that Viralgen serves as the commercial manufacturing partner for the gene therapy program and plays an important role in advancing production capabilities required for future regulatory filings and potential market launch. Executives stated that the collaboration reflects the growing importance of robust manufacturing infrastructure within the rapidly evolving gene therapy industry.
Gene Therapy Platform Targets Severe Neurodegenerative Diseases
Myrtelle continues to position itself as a clinical-stage biotechnology company focused on developing transformative gene therapies for severe neurodegenerative diseases. The company’s proprietary platform supports multiple investigational approaches targeting neurological disorders driven by well-defined genetic mutations. MYR-101 remains the company’s lead clinical program and is supported through an exclusive worldwide licensing agreement with Pfizer for the Canavan disease program.
Company leadership believes oligodendrocyte-targeted gene therapy may represent an important advancement for diseases involving myelin dysfunction and central nervous system degeneration. The company also emphasized that the ongoing ASGCT presentations provide additional visibility into the broader scientific progress occurring within rare disease gene therapy research. As regulatory agencies continue encouraging innovation through accelerated development pathways and pilot programs, Myrtelle aims to further expand clinical evidence supporting MYR-101 while advancing toward future regulatory milestones and potential commercialization opportunities for patients affected by devastating pediatric neurological disorders.
Source: Myrtelle press release
